EP0111144B1 - Sustained release solid dosage forms having non-uniform distribution of active ingredient - Google Patents

Sustained release solid dosage forms having non-uniform distribution of active ingredient Download PDF

Info

Publication number
EP0111144B1
EP0111144B1 EP83110874A EP83110874A EP0111144B1 EP 0111144 B1 EP0111144 B1 EP 0111144B1 EP 83110874 A EP83110874 A EP 83110874A EP 83110874 A EP83110874 A EP 83110874A EP 0111144 B1 EP0111144 B1 EP 0111144B1
Authority
EP
European Patent Office
Prior art keywords
medicament
sustained
release
core
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP83110874A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0111144A1 (en
Inventor
Michael A. Zoglio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruppo Lepetit SpA
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Priority to AT83110874T priority Critical patent/ATE23948T1/de
Publication of EP0111144A1 publication Critical patent/EP0111144A1/en
Application granted granted Critical
Publication of EP0111144B1 publication Critical patent/EP0111144B1/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • sustained-action dosage forms provide rapid availability and maintenance of medicament at a level sufficient to provide a desired biological effect.
  • the sustained-action dosage forms are to be distinguished from prolonged-action dosage forms which provide an initial amount of medicament which may exceed the upper limit of the desirable therapeutic range and which subsequently will provide medicament within the desirable therapeutic range for a longer time than will a conventional dosage form.
  • sustained-action dosage forms operate as prolonged-action dosages and merely mimic the desired sustained-release effect. L. Lachman, H. A. Lieberman and J. L. Kanig, The Theory and Practice of Industrial Pharmacy, Lea and Febiger, 1970, page 409.
  • pharmaceutical dosage forms contain an active component distributed uniformly throughout.
  • uniform concentration leads to a non-linear, i.e., non-zero order, release profile.
  • the surface area exposed to dissolution diminishes with time, thereby causing a reduction in drug-release rate.
  • rate of release is dependent on the gradient of drug concentration between the dosage form and dissolution environment. Depletion of drug from the system causes a reduction in this gradient which slows release rate.
  • non-uniform concentration can be used as a means of countering diffusion or erosion effects.
  • FR-A-2 331 375 describes a method of preparing granules having a continuously decreasing concentration of active component from the center to the surface.
  • the granule is prepared by continuously coating a particle with a composition containing progressive less of the active ingredient.
  • the granules may be used to prepare pharmaceutical tablets and capsules with controlled release of the active component.
  • Applicant's novel dosage forms provide for zero-order release of active ingredient and are suitable for use in sustained release formulations.
  • the desired release of medicament is accomplished by preparing a solid dosage form having a core and one or more concentric enveloping layers or press coats wherein the concentration of medicament is greatest in the core and diminishes in each subsequent outer layer.
  • a solid dosage form having such a distribution of medicament avoids the non-linear release of prior art solid dosage forms having uniform distribution of active ingredients.
  • applicant's dosage forms erode, reducing available surface area, the greater drug concentration in the core negates the diminishment of drug-release rate.
  • non-uniform distribution eliminates the reduction of gradient inherent in diffusing dosage forms having uniform drug distribution.
  • compositions having a core and one or more enveloping sustained-release layers, the core and sustained-release enveloping layers consisting essentially of a mixture containing medicament, hydrophilic gel and excipients, wherein the concentration of hydrophilic gel in the core and in each sustained-release enveloping layer is essentially constant, provide for a substantially zero-order release of medicament.
  • the amount of medicament in either the core or in any given sustained-release layer is determined by the formula wherein D L is the amount of medicament in the core or in any given sustained-reiease layer, D T is the total amount of medicament in the sustained-release portion of the tablet, R D is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined and R T is the radius of the sustained-release portion of the tablet.
  • Solid dosage forms include pressed or compressed tablets, molded tablets, pills and extruded suppositories. Compressed tablets are preferred because of ease in manufacturing and consumer acceptance.
  • Applicant's solid-dosage forms have a central core and one or more concentric enveloping sustained-release layers or press coats. Ideally, there would be an infinite number of sustained-release layers of infinitesimally small thickness. For practical reasons, primarily due to the limitation of presently available tableting machinery, ten (10) or so layers over the core would be the uppermost limit.
  • the Manesty Bicota@ manufactured by Manesty Machines Limited, can produce a triple pressed tablet from three separate granulations and a fourth coat can be pressed on by using a device to recycle the triple pressed tablet.
  • Applicant's preferred solid-dosage form is a tablet having a core and from 1 to 4 enveloping layers. More preferably, the dosage form would have a core and one enveloping layer.
  • one or more outer layers may be used to effect a variety of purposes other than sustained release.
  • tablets may be coated to protect the ingredients from the atmosphere, to mask unpleasant taste, to improve appearance, to control the site of action of the drug such as an enteric coating, and to provide a rapidly dissolving outer layer to provide for quick onset of action followed by zero order sustained release.
  • These optional layers may be accomplished by sugar coating, film coating, compression coating and any other method known to the art.
  • an outer, quickly-dissolving, non-sustained release layer would contain medicament needed for rapid onset of action and several inner, sustained-release layers and core would contain additional amounts of the medicament or would optionally contain a second medicament whose sustained-release action would compliment the effect of the medicament in the outer, non-sustained release layer.
  • a preferred tablet of applicant's invention has a core and 3 enveloping layers wherein the quickly-dissolving, outermost layer contains terfenadine, an antihistamine, and wherein the sustained-release core and inner layers contain pseudoephedrine hydrochloride, a bronchodilator.
  • the core and the enveloping layers may be any thickness but solid dosage forms in excess of 25.4 mm thick are quite undesirable from the consumer's point of view. Although it is highly desirable to have a multitude of very thin layers, practical limitations render this goal quite difficult to attain. For example, current tableting technology precludes press-coated layers less than about 0.8 mm thick. Extruded solid dosage forms cannot have layers less than about 1 mm thick. Applicant prefers 1 to 4 press coated layers over a central core, wherein the layers are about 2.4 mm thick.
  • hydrophilic gels are any substance which gels when in contact with water, and swells slowly from the outer surface to the core resulting in diffusion or erosion of the drug from the swollen matrix. Substances having these properties are well known to those skilled in the pharmaceutical arts.
  • hydrophilic gels for use in the present invention are hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl ethylcellulose, methylcellulose, carboxyethylcellulose, carboxymethyl hydroxyethylcellulose, methylcellulose cross-linked with dialdehyde, Carbopol@, polyvinyl alcohol cross-linked with glyoxal, formaldehyde or glutaraldehyde, poly(N-vinyl-2-pyrrolidone), poly(hydroxyalkyl methacrylate), esters of 2-hydroxyethyl methacrylate, acrylates such as Aquakeeps@, N-vinyl lactams, poly acrylic acids such as Goodrite@, poly acrylamides such as Cyanamer@, maleic anhydride plus styrene co-polymer, maleic anhydride plus ethylene propylene, butylene or isobutylene co-pol
  • the same hydrophilic gel or mixture of hydrophilic gels must be utilized in the core and sustained-release enveloping layers in order that applicant's mathematical expression be useful in determining the appropriate quantity of medicament.
  • a tablet could be prepared providing substantially zero order release of medicament.
  • applicant's mathematical expression would not predict the amounts of medicament to be used in the core and layers.
  • Applicant prefers HPMC, particularly HPMC having a viscosity of 4000 mPa.s, as a hydrophilic gel for use in the present invention.
  • Applicant also prefers a mixture of hydrophilic gels containing 1 part of HPMC having a viscosity of 4000 mPa.s and 3 parts of HPMC having a viscosity of 100 mPa.s.
  • Applicant's tablets can contain one or more excipients in addition to the medicament and hydrophilic gel. With the exception of tablet disintegrants, which tend to break apart the tablet, any other pharmaceutical excipient may be used. Suitable tablet excipients for use in applicant's tablets are, for example, diluents such as lactose, dextrose, mannitol, sorbitol, gelatin, acacia, dicalcium phosphate, tricalcium phosphate or monocalcium phosphate; binders such as.
  • lubricants such as stearic acid, zinc, calcium or magnesium stearate, or talc
  • colorants such as FD&C dyes (i.e. dyes permissible in food, drugs and cosmetics), and flavoring agents.
  • diluents mannitol and lactose
  • lubricant zinc stearate
  • Medicaments which are suitable for use in the solid dosage forms of this invention include any drug substance or combination of drug substances which can be formulated in a solid dosage form and for which sustained release administration would be desirable.
  • Suitable drug substances and their indications are acetaminophen, an antipyretic; aminophylline, a smooth muscle relaxant; amitriptyline HCI, an antidepressant; betamethasone phosphate, a glucocorticoid; brompheniramine maleate, an antihistaminic; buphenine HCI, a peripheral vasodilator; carbetapentane citrate, an antitussive; carbocromene HCI, a coronary vasodilator; chlorpheniramine maleate, an antihistaminic; chlorpromazine HCI, a tranquilizer; clonidine HCI; an antihypertensive; codeine phosphate, an antitussive; diethylpropion HCI, an anorexiant; di
  • sustained release administration is contraindicated or is of questionable value for a) drugs with long biological half lives (i.e., greater than 10 hours) such as chlorpromazine and thioridazine; b) drugs absorbed by active transport, as for example, quaternary ammonium compounds such as propantheline bromide; c) antibiotics such as penicillins and cephalosporins; d) drugs destroyed by first pass liver metabolism and/or metabolism in the gut wall such as ritodrine, salicylamide or lidocaine; and drugs that are naturally sustained release, for example, medicaments which are absorbed in body fat and subsequently are slowly released into the patients blood, such as chlorpromazine and thioridazine.
  • drugs with long biological half lives i.e., greater than 10 hours
  • drugs absorbed by active transport as for example, quaternary ammonium compounds such as propantheline bromide
  • antibiotics such as penicillins and cephalosporins
  • any amount of medicament can be formulated into the solid dosage forms of the present invention. Due to the limitations on the size of the dosage from and the large amount of medicament necessary in the core, dosage forms of this invention should not exceed about 500 mg of medicament. Applicant prefers dosage forms having 300 mg or less of medicament. Dosage forms of this invention having greater than 300 mg of medicament will require departure from cylindrical shapes to oval or capsule shaped forms in order to accommodate the high concentration-of medicament in the core of the dosage form. In principle, there is no lower limit on the amount of medicament which can be formulated into the dosage forms of this invention. However, applicant prefers dosage-forms having at least 0.1 mg of medicament.
  • the rate of medicament release from applicant's tablets is determined by medicant concentration as well as the hydrophilic gel and its concentration. Other factors, such as compression force in pressed tablets, appear to have little, if any, effect.
  • the relationship between release rate and medicament concentration is linear, that is, as the medicament concentration is doubled, for example, the release rate is likewise doubled.
  • Reducing the hydrophilic gel concentration in a given dosage form increases the release rate of the medicament in a semi-logarithmic manner. That is, by reducing the concentration of a given hydrophilic gel by half in an otherwise identical dosage form, the release rate of the medicament would increase by a factor of approximately 1.25.
  • the sustained dosage forms of applicant's invention are intended to effect substantially zero order release of medicament from 1 hour to 2 days, preferably from 4 to 24 hours, more preferably from 8 to 12 hours depending on medicament concentration as we)! as the hydrophilic gel and its concentration.
  • concentration of hydrophilic gel in the core and sustained-release, enveloping layers must be essentially constant.
  • the solid dosage forms of this invention can be of any shape, however, in using applicant's mathematical expression, it will be necessary to orient, at least conceptually, the shape of the dosage form to correspond to a cylinder and designate lines thru the center of the dosage form corresponding to the cylindrical axis of height and radial axis.
  • the axis of height extends from the center of one convex surface to the other through the center of the tablet.
  • the radial axis extends outward from the axis of height at the tablets center to the circular edge.
  • the axis of height and radial axis are readily apparent by analogy to a cylindrical solid.
  • the applicant has derived a mathematical expression based on certain theoretical considerations. Although the derivation of this expression was based on solid dosage forms having the shape of a cylindrical solid and solid dosage forms which release medicament by erosion, the resulting expression has been found to be useful in dosage forms of a variety of shapes and dosage forms which release medication by diffusion as well as erosion.
  • the differential radius of a given dosage form is the thickness of the core or a given layer measured along the radial axis.
  • the differential radius is the distance from the center of the tablet to the outer edge of the core measured along the radial axis.
  • the differential radius of a given layer is the distance from the inner edge to the outer edge of a given layer measured along the radial axis.
  • an average value for differential radius should be used.
  • the length of the radial axis will vary depending on whether the axis extends outward toward a corner of the tablet edge, toward a face of the tablet edge or toward a point in between.
  • D L is the amount of medicament in the core or in any given layer
  • D T is the total amount of medicament in the sustained-release portion of the tablet
  • R D is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined
  • R T is the radius of the sustained-release portion of the tablet.
  • the diffusion equation is: wherein D L , D T and R T are as in the erosion expression above and wherein R SD is the squared differential radius.
  • the squared differential radius for a given sustained release layer or the core is the difference between the square of the distance from the outer surface of the sustained-release portion of the tablet to the inner edge of the layer to be determined (the center of the tablet for the core) and the square of the distance from the outer surface of the sustained-release portion of the tablet to the outer edge of the layer to be determined (zero for the outermost layer) measured along the radial axis of the tablet. Average values should be used for irregularly shaped dosage forms.
  • the latter expression theoretically works better for diffusing dosage forms and thus constitutes a preferred embodiment of this invention, the applicant nevertheless prefers the former erosion expression for use in calculating doses for all solid dosage forms of this invention.
  • a tablet of this invention wherein the distribution of medicament in the core and sustained release layers is determined by means of the above-mentioned mathematical expression, will release medication in a substantially zero-order fashion. That is, the amount of medicament released from a tablet of applicant's invention per unit of time will remain essentially constant until all medicament is released. While the release is normally substantially constant, in some instances there may be an initial release of medicament in a first order fashion, that is, initially more medicament will be released per unit of time than will be released during a subsequent unit of time which more closely imitates the desired zero-order release. The excess amount of medication released is said to be "dumped". This dumping effect occurs prior to and during the time period in which the tablet's hydrophilic gel layers are swelling to form a barrier to retard further release of medicament. Normally, this dumping period will not exceed a few hours, generally it does not exceed about 1 hour.
  • the dumped medication originates from the outermost sustained release layer
  • the typically, substantially zero-order release of medicament achieved by applicant's tablets can approximate constant release even more closely and any initial dumping of medicament reduced to negligible amounts, by transferring some of the medication from the outermost sustained release layer to the inner layers or core.
  • this is accomplished by transferring an amount of medicament from the outermost sustained release layer to the penultimate sustained release layer or in the case of a tablet having only 1 sustained release layer, transferring some of the medicament from the sustained release layer to the core.
  • the amount of medicament to be transferred from the outermost sustained release layer in order to reduce the dumping effect is approximately equal to the amount of medicament "dumped". Because all of the medicament dumped is assumed to come from the outermost sustained release layer in the first hour, the amount of medicament dumped is approximately equal to the difference between the amount of medicament released in the first hour and the amount released in any subsequent hour.
  • the tablet has a core wherein the axis of length is 14.3 mm long and the radial axis measures 2.8 mm.
  • the middle layer has an axis of length equal to 16.7 mm and the distance from the tablets center to the outer edge of the layer measured along the radial axis is 4 mm.
  • the outer layer has an axis of length equal to 19 mm and the distance from the tablets center to the outer edge measured along the radial axis is 5.2 mm.
  • the total amount of medicament is equal to 500 mg.
  • the total radius measured along the radial axis is 5.2 mm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP83110874A 1982-11-01 1983-10-31 Sustained release solid dosage forms having non-uniform distribution of active ingredient Expired EP0111144B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT83110874T ATE23948T1 (de) 1982-11-01 1983-10-31 Feste dosierungsformen mit verzoegerter freigabe, die keine einheitliche verteilung des aktiven stoffes aufweisen.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43810082A 1982-11-01 1982-11-01
US438100 1982-11-01
US53612883A 1983-09-27 1983-09-27
US536128 1983-09-27

Publications (2)

Publication Number Publication Date
EP0111144A1 EP0111144A1 (en) 1984-06-20
EP0111144B1 true EP0111144B1 (en) 1986-12-03

Family

ID=27031546

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83110874A Expired EP0111144B1 (en) 1982-11-01 1983-10-31 Sustained release solid dosage forms having non-uniform distribution of active ingredient

Country Status (13)

Country Link
EP (1) EP0111144B1 (enrdf_load_html_response)
KR (1) KR900007311B1 (enrdf_load_html_response)
AU (1) AU554377B2 (enrdf_load_html_response)
CA (1) CA1220137A (enrdf_load_html_response)
DE (1) DE3368011D1 (enrdf_load_html_response)
DK (1) DK499183A (enrdf_load_html_response)
ES (1) ES8607008A1 (enrdf_load_html_response)
GR (1) GR78740B (enrdf_load_html_response)
IE (1) IE56182B1 (enrdf_load_html_response)
IL (1) IL70071A (enrdf_load_html_response)
NO (1) NO163356C (enrdf_load_html_response)
NZ (1) NZ206094A (enrdf_load_html_response)
PH (1) PH20332A (enrdf_load_html_response)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709022B2 (en) 2000-06-26 2010-05-04 Bayer Schering Pharma Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
US7884122B2 (en) 2007-06-08 2011-02-08 Shionogi Pharma, Inc. Extended release formulation and method of treating adrenergic dysregulation
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
DE10075031I2 (de) * 1984-08-17 2004-07-01 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
AU675557B2 (en) * 1993-06-14 1997-02-06 Janssen Pharmaceutica N.V. Extended release, film-coated tablet of astemizole and pseudoephedrine
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
DE19608423A1 (de) * 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
KR100402053B1 (ko) * 2000-09-28 2003-10-17 한국화학연구원 항생제의 서방성 임플란트 제제
WO2003037244A2 (en) * 2001-10-29 2003-05-08 Therics, Inc. System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10702548B2 (en) 2015-03-04 2020-07-07 Joelle Michele Forbes Compositions and methods for treating drug addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1139869A (en) * 1966-01-06 1969-01-15 Moore Medicinal Products Ltd Improvements in or relating to tablets
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709022B2 (en) 2000-06-26 2010-05-04 Bayer Schering Pharma Ag Sustained-release preparations of quinolone antibiotics and method for preparation thereof
US7780986B2 (en) 2000-06-26 2010-08-24 Bayer Schering Pharma Ag Method of preparing sustained-release preparations of quinolone antibiotics
US8187632B2 (en) 2000-06-26 2012-05-29 Bayer Schering Pharma Ag Sustained-release preparations of quinolone antibiotics
US7884122B2 (en) 2007-06-08 2011-02-08 Shionogi Pharma, Inc. Extended release formulation and method of treating adrenergic dysregulation
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms

Also Published As

Publication number Publication date
KR840006765A (ko) 1984-12-03
NZ206094A (en) 1986-10-08
NO163356B (no) 1990-02-05
DE3368011D1 (en) 1987-01-15
GR78740B (enrdf_load_html_response) 1984-10-02
IL70071A0 (en) 1984-01-31
IL70071A (en) 1987-12-31
IE56182B1 (en) 1991-05-08
NO163356C (no) 1990-05-16
EP0111144A1 (en) 1984-06-20
KR900007311B1 (ko) 1990-10-08
PH20332A (en) 1986-12-02
ES526901A0 (es) 1986-06-16
CA1220137A (en) 1987-04-07
DK499183D0 (da) 1983-10-31
NO833961L (no) 1984-05-02
IE832543L (en) 1984-05-01
ES8607008A1 (es) 1986-06-16
AU554377B2 (en) 1986-08-21
AU2080383A (en) 1984-05-10
DK499183A (da) 1984-05-02

Similar Documents

Publication Publication Date Title
EP0111144B1 (en) Sustained release solid dosage forms having non-uniform distribution of active ingredient
CA2082740C (en) Controlled release device
US6033685A (en) Tablet for the controlled release of active agents
US4610870A (en) Controlled release formulation
EP1416920B1 (en) Multiplex drug delivery system suitable for oral administration
US5439687A (en) Dosage forms having zero-order dihydropyridine calcium antagonist release
EP1589951B1 (en) Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
EP1499300B1 (en) Pharmaceutical formulations with improved bioavailability
CA2217226A1 (en) Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0656204A1 (en) Controlled release pharmaceutical tablet having lenticular form
EP0776660A2 (en) Long-lasting release nifedipine preparation
SK30396A3 (en) Beads, method for producing them and a pharmaceutical preparation containing the same
MXPA97001465A (en) Formulation of acetaminofeno, liberacion sosten
EP0516141A1 (en) Pharmaceutical controlled-release composition with bioadhesive properties
CZ189597A3 (cs) Dávkovací prostředek pro řízené uvolňování suspenze léčiva
EP1558935B1 (en) Controlled-release compositions
WO2000010537A1 (en) Timed release tablet comprising naproxen and pseudoephedrine
WO2009118763A1 (en) Multilayered pharmaceutical compositions and processes thereof
EP0126453B1 (en) Controlled release tablet
JPS5995214A (ja) 活性成分の不均質分布をもつ持効性固体適量形式
EP0557244B1 (en) Dosage forms having prolonged active-ingredient release
EP1450783A1 (en) New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
EP1107740A1 (en) Timed release tablet comprising naproxen and pseudoephedrine
ITMI980557A1 (it) Composizioni farmaceutiche a rilascio modificato contenenti principi attivi ad attivita calcio antagonista

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19840816

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 23948

Country of ref document: AT

Date of ref document: 19861215

Kind code of ref document: T

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3368011

Country of ref document: DE

Date of ref document: 19870115

ITF It: translation for a ep patent filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19920831

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19920902

Year of fee payment: 10

Ref country code: CH

Payment date: 19920902

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920916

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19920918

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19920919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19921001

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19921030

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19921031

Year of fee payment: 10

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19931031

Ref country code: LI

Effective date: 19931031

Ref country code: GB

Effective date: 19931031

Ref country code: CH

Effective date: 19931031

Ref country code: BE

Effective date: 19931031

Ref country code: AT

Effective date: 19931031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19931101

BERE Be: lapsed

Owner name: MERRELL DOW PHARMACEUTICALS INC.

Effective date: 19931031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19940501

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19931031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19940630

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19940701

ITPR It: changes in ownership of a european patent

Owner name: CAMBIO DOMICILIO MANDATARIO;GRUPPO LEPETIT S.P.A.

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 83110874.1

Effective date: 19940610